Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

Background Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL d...

Full description

Saved in:
Bibliographic Details
Published inAlzheimer's research & therapy Vol. 10; no. 1; pp. 113 - 6
Main Authors Sánchez-Valle, Raquel, Heslegrave, Amanda, Foiani, Martha S., Bosch, Beatriz, Antonell, Anna, Balasa, Mircea, Lladó, Albert, Zetterberg, Henrik, Fox, Nick C.
Format Journal Article
LanguageEnglish
Published London BioMed Central 03.11.2018
BioMed Central Ltd
BMC
Subjects
Alzheimer's disease
Amyotrophic lateral sclerosis
association
biomarker
Biomarkers
Biomedical and Life Sciences
Biomedicine
Care and treatment
chain
Cytoplasmic filaments
Dementia
Familial Alzheimer's disease
frontotemporal dementia
Geriatric Psychiatry
Geriatrics/Gerontology
Immunoassay
Light
Multiple sclerosis
Mutation
Neurodegeneration
Neurofilament light
Neurologi
Neurology
Neurosciences
Neurosciences & Neurology
Presenilin 1
Prevention
protein
Quality control
trials
Biomarkers
Neurofilament light
Alzheimer’s disease
Presenilin 1
Familial Alzheimer’s disease
Online AccessGet full text
ISSN1758-9193
1758-9193
DOI10.1186/s13195-018-0439-y

Cover

Abstract Background Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups. Methods Serum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests. Results Forty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho = 0.75, p  < 0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho = 0.70, p  < 0.001) and cognitive (rho = −0.77, p  < 0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho = 0.72, 0.71, and 0.71, respectively, all p  < 0.001). Serum NfL concentration was higher in SMC than in AMC and CTR. Conclusions Serum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.
AbstractList Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer's disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups. Serum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests. Forty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho = 0.75, p < 0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho = 0.70, p < 0.001) and cognitive (rho = -0.77, p < 0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho = 0.72, 0.71, and 0.71, respectively, all p < 0.001). Serum NfL concentration was higher in SMC than in AMC and CTR. Serum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.
Abstract Background Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups. Methods Serum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests. Results Forty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho = 0.75, p < 0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho = 0.70, p < 0.001) and cognitive (rho = −0.77, p < 0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho = 0.72, 0.71, and 0.71, respectively, all p < 0.001). Serum NfL concentration was higher in SMC than in AMC and CTR. Conclusions Serum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.
Background Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer's disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups. Methods Serum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests. Results Forty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho = 0.75, p < 0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho = 0.70, p < 0.001) and cognitive (rho = -0.77, p < 0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho = 0.72, 0.71, and 0.71, respectively, all p < 0.001). Serum NfL concentration was higher in SMC than in AMC and CTR. Conclusions Serum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD. Keywords: Alzheimer's disease, Biomarkers, Familial Alzheimer's disease, Presenilin 1, Neurofilament light
Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer's disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups. Serum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests. Forty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho = 0.75, p < 0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho = 0.70, p < 0.001) and cognitive (rho = -0.77, p < 0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho = 0.72, 0.71, and 0.71, respectively, all p < 0.001). Serum NfL concentration was higher in SMC than in AMC and CTR. Serum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.
Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer's disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups.BACKGROUNDBiomarkers that can track disease onset and progression in autosomal dominant Alzheimer's disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups.Serum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests.METHODSSerum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests.Forty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho = 0.75, p < 0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho = 0.70, p < 0.001) and cognitive (rho = -0.77, p < 0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho = 0.72, 0.71, and 0.71, respectively, all p < 0.001). Serum NfL concentration was higher in SMC than in AMC and CTR.RESULTSForty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho = 0.75, p < 0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho = 0.70, p < 0.001) and cognitive (rho = -0.77, p < 0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho = 0.72, 0.71, and 0.71, respectively, all p < 0.001). Serum NfL concentration was higher in SMC than in AMC and CTR.Serum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.CONCLUSIONSSerum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.
Background Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups. Methods Serum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests. Results Forty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho = 0.75, p  < 0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho = 0.70, p  < 0.001) and cognitive (rho = −0.77, p  < 0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho = 0.72, 0.71, and 0.71, respectively, all p  < 0.001). Serum NfL concentration was higher in SMC than in AMC and CTR. Conclusions Serum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.
BackgroundBiomarkers that can track disease onset and progression in autosomal dominant Alzheimer's disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups.MethodsSerum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests.ResultsForty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho=0.75, p<0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho=0.70, p<0.001) and cognitive (rho=-0.77, p<0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho=0.72, 0.71, and 0.71, respectively, all p<0.001). Serum NfL concentration was higher in SMC than in AMC and CTR.ConclusionsSerum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.
Background Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups. Methods Serum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests. Results Forty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho = 0.75, p < 0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho = 0.70, p < 0.001) and cognitive (rho = −0.77, p < 0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho = 0.72, 0.71, and 0.71, respectively, all p < 0.001). Serum NfL concentration was higher in SMC than in AMC and CTR. Conclusions Serum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.
ArticleNumber 113
Audience Academic
Author Bosch, Beatriz
Sánchez-Valle, Raquel
Zetterberg, Henrik
Antonell, Anna
Balasa, Mircea
Foiani, Martha S.
Fox, Nick C.
Heslegrave, Amanda
Lladó, Albert
Author_xml – sequence: 1
  givenname: Raquel
  orcidid: 0000-0001-7750-896X
  surname: Sánchez-Valle
  fullname: Sánchez-Valle, Raquel
  email: rsanchez@clinic.cat
  organization: Alzheimer’s Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Institut d’Investigació Biomèdica August Pi i Sunyer, University of Barcelona
– sequence: 2
  givenname: Amanda
  surname: Heslegrave
  fullname: Heslegrave, Amanda
  organization: Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, UK Dementia Research Institute at UCL
– sequence: 3
  givenname: Martha S.
  surname: Foiani
  fullname: Foiani, Martha S.
  organization: Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, UK Dementia Research Institute at UCL
– sequence: 4
  givenname: Beatriz
  surname: Bosch
  fullname: Bosch, Beatriz
  organization: Alzheimer’s Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Institut d’Investigació Biomèdica August Pi i Sunyer, University of Barcelona
– sequence: 5
  givenname: Anna
  surname: Antonell
  fullname: Antonell, Anna
  organization: Alzheimer’s Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Institut d’Investigació Biomèdica August Pi i Sunyer, University of Barcelona
– sequence: 6
  givenname: Mircea
  surname: Balasa
  fullname: Balasa, Mircea
  organization: Alzheimer’s Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Institut d’Investigació Biomèdica August Pi i Sunyer, University of Barcelona
– sequence: 7
  givenname: Albert
  surname: Lladó
  fullname: Lladó, Albert
  organization: Alzheimer’s Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Institut d’Investigació Biomèdica August Pi i Sunyer, University of Barcelona
– sequence: 8
  givenname: Henrik
  surname: Zetterberg
  fullname: Zetterberg, Henrik
  organization: Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, UK Dementia Research Institute at UCL, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg
– sequence: 9
  givenname: Nick C.
  surname: Fox
  fullname: Fox, Nick C.
  organization: UK Dementia Research Institute at UCL, Dementia Research Centre, University College of London, Institute of Neurology
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30390718$$D View this record in MEDLINE/PubMed
https://gup.ub.gu.se/publication/273700$$DView record from Swedish Publication Index
BookMark eNp9k81u1DAQxyNURD_gAbigSEiIS4odJ7FzQVpVfFSqxAE4W15nkvXi2MVOWi0n7jwBr8eTMGm2dLcCFCmxJr__f-zxzHFy4LyDJHlKySmlonoVKaN1mREqMlKwOts8SI4oL0VW05od7KwPk-MY14RUVS6KR8khI6wmnIqj5MdHCGOfOhiDb41VPbghtaZb4RuuwMZU-xDAqgHSazOs0ojRYIZN2oOKY4CYKtfM-gY6cBDUYLxLexW-QIipcakaBx99r2za-N44hRkW9tsKTA_h1_efMW1MRDN4nDxslY3wZPs9ST6_ffPp7H128eHd-dniItMVz4dMk5azBgpBWKF5KzRrGNRCCaZqRsmyoERzUiu6LHNdaiUELPOcMk5ZhQxhJ8n57Nt4tZaXweBeN9IrI28CPnRShcFoC5LQkqCEMJ23BW9AYcVbLYiolqwGXaBXNnvFa7gcl3tu3XgpMdSNMoLMOeNkyv165hHuodFY7qDsnmz_jzMr2fkrWeW0ZIyjwcutQfBfR4iD7E3UYK1y4Mco8aCElCUTE_r8Hrr2Y3BY2okqi4qTvLqjOoUHNq71mFdPpnJRVryuGOUCqdO_UPg00BuNbYnNA_uCFzuCFSg7rKK349QccR98tluRP6W47VEE-Azo4GMM0Epthpsmwy0YKymR0zTIeRrwyoScpkFuUEnvKW_N_6fJtxeKrOsg3BXt36LfqL8fFA
CitedBy_id crossref_primary_10_1186_s12883_024_03728_7
crossref_primary_10_1111_ene_14689
crossref_primary_10_1136_jnnp_2018_320106
crossref_primary_10_2174_1567205020666230601123123
crossref_primary_10_3233_JAD_215093
crossref_primary_10_1016_j_jneumeth_2021_109281
crossref_primary_10_3233_JAD_201167
crossref_primary_10_1177_1756286419888819
crossref_primary_10_3390_jpm10040221
crossref_primary_10_2217_bmm_2021_0219
crossref_primary_10_1016_j_msard_2021_103280
crossref_primary_10_1136_jnnp_2020_325537
crossref_primary_10_1016_j_arr_2024_102290
crossref_primary_10_3390_brainsci10010056
crossref_primary_10_3389_fnins_2022_837390
crossref_primary_10_1186_s13195_019_0472_5
crossref_primary_10_1002_acn3_51234
crossref_primary_10_1007_s40520_022_02095_y
crossref_primary_10_3390_jpm10030061
crossref_primary_10_1186_s12916_022_02425_x
crossref_primary_10_1016_j_gim_2022_10_005
crossref_primary_10_1093_jn_nxab381
crossref_primary_10_1007_s11357_025_01567_z
crossref_primary_10_1016_j_cll_2020_05_003
crossref_primary_10_3389_fcimb_2023_1090013
crossref_primary_10_1016_j_neurobiolaging_2023_04_013
crossref_primary_10_1002_acn3_51402
crossref_primary_10_1016_j_conb_2020_02_001
crossref_primary_10_1016_S1474_4422_21_00129_0
crossref_primary_10_1016_j_ebiom_2024_105327
crossref_primary_10_1007_s00415_019_09567_8
crossref_primary_10_1007_s10654_024_01131_7
crossref_primary_10_1016_j_nbd_2020_104960
crossref_primary_10_1016_j_dadm_2019_08_009
crossref_primary_10_3389_fnins_2021_695049
crossref_primary_10_3389_fnagi_2022_900773
crossref_primary_10_3390_biom14010093
crossref_primary_10_3233_JAD_231084
crossref_primary_10_1016_j_neuropharm_2020_108081
crossref_primary_10_1136_bmjno_2021_000143
crossref_primary_10_3389_fnagi_2019_00254
crossref_primary_10_1111_joim_13332
crossref_primary_10_1007_s11357_023_00876_5
crossref_primary_10_1016_j_neurobiolaging_2020_05_011
crossref_primary_10_1016_S1474_4422_21_00361_6
crossref_primary_10_1186_s13195_023_01221_w
crossref_primary_10_1016_j_pneurobio_2024_102574
crossref_primary_10_1038_s41598_021_92887_5
crossref_primary_10_1002_alz_12248
crossref_primary_10_3389_fnagi_2022_1034684
crossref_primary_10_2174_1570159X19666210524153901
crossref_primary_10_1016_j_jad_2025_01_045
crossref_primary_10_3233_JAD_190322
crossref_primary_10_25122_jml_2022_0251
crossref_primary_10_1016_j_ejpn_2021_04_002
crossref_primary_10_1186_s40478_021_01259_7
Cites_doi 10.1016/j.jalz.2013.01.010
10.1002/acn3.325
10.1159/000322229
10.1001/jamaneurol.2016.6117
10.1016/j.neurol.2013.07.017
10.1212/WNL.0000000000004667
10.1002/ana.24954
10.1002/acn3.290
10.1186/alzrt59
10.1212/WNL.0000000000003154
10.1002/ana.22247
10.1016/j.neurobiolaging.2014.12.022
10.1038/srep38737
10.1056/NEJMoa1202753
10.1016/j.neuron.2016.06.030
10.1002/ana.24552
10.1016/S1474-4422(17)30124-2
10.1212/WNL.0000000000001642
10.1016/j.jalz.2012.12.004
10.1126/scitranslmed.3007901
ContentType Journal Article
Copyright The Author(s). 2018
COPYRIGHT 2018 BioMed Central Ltd.
Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s). 2018
– notice: COPYRIGHT 2018 BioMed Central Ltd.
– notice: Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ADTPV
AOWAS
F1U
DOA
DOI 10.1186/s13195-018-0439-y
DatabaseName SpringerOpen Free (Free internet resource, activated by CARLI)
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
SwePub
SwePub Articles
SWEPUB Göteborgs universitet
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList


PubMed
MEDLINE - Academic



Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
EISSN 1758-9193
EndPage 6
ExternalDocumentID oai_doaj_org_article_01503a003c2f47dea131fc8086b39ec4
oai_gup_ub_gu_se_273700
PMC6215337
A567963178
30390718
10_1186_s13195_018_0439_y
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Wellcome Trust Multi-User Equipment Grant
– fundername: UK Dementia Research Institute
– fundername: the Leonard Wolfson Experimental Neurology Centre
– fundername: European Research Council
  funderid: http://dx.doi.org/10.13039/501100000781
– fundername: Instituto de Salud Carlos III
  grantid: PI160235
  funderid: http://dx.doi.org/10.13039/501100004587
– fundername: Wellcome Trust
– fundername: Instituto de Salud Carlos III
  grantid: PI160235
– fundername: ;
– fundername: ;
  grantid: PI160235
GroupedDBID ---
0R~
23M
2WC
53G
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFS
ACIHN
ACJQM
ACUHS
ADBBV
ADUKV
AEAQA
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
DIK
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
HZ~
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M~E
O5R
O5S
O9-
OK1
P2P
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
AAYXX
ALIPV
CITATION
NPM
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
4.4
ADTPV
AHSBF
AOWAS
F1U
ID FETCH-LOGICAL-c672t-c0f73de48034c7f8c3d3e98a83a9310b410c709a1b52c5ca88eb2213713683a03
IEDL.DBID C6C
ISSN 1758-9193
IngestDate Wed Aug 27 01:27:50 EDT 2025
Tue Sep 09 23:26:22 EDT 2025
Thu Aug 21 14:24:22 EDT 2025
Thu Sep 04 23:14:23 EDT 2025
Fri Jul 25 07:16:50 EDT 2025
Tue Jun 17 21:06:12 EDT 2025
Tue Jun 10 20:47:38 EDT 2025
Thu May 22 21:00:53 EDT 2025
Thu Apr 03 07:05:39 EDT 2025
Thu Apr 24 22:51:24 EDT 2025
Tue Jul 01 02:38:48 EDT 2025
Sat Sep 06 07:34:46 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Biomarkers
Neurofilament light
Alzheimer’s disease
Presenilin 1
Familial Alzheimer’s disease
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c672t-c0f73de48034c7f8c3d3e98a83a9310b410c709a1b52c5ca88eb2213713683a03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-7750-896X
OpenAccessLink https://doi.org/10.1186/s13195-018-0439-y
PMID 30390718
PQID 2135467026
PQPubID 2040174
PageCount 6
ParticipantIDs doaj_primary_oai_doaj_org_article_01503a003c2f47dea131fc8086b39ec4
swepub_primary_oai_gup_ub_gu_se_273700
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6215337
proquest_miscellaneous_2130055387
proquest_journals_2135467026
gale_infotracmisc_A567963178
gale_infotracacademiconefile_A567963178
gale_healthsolutions_A567963178
pubmed_primary_30390718
crossref_citationtrail_10_1186_s13195_018_0439_y
crossref_primary_10_1186_s13195_018_0439_y
springer_journals_10_1186_s13195_018_0439_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-11-03
PublicationDateYYYYMMDD 2018-11-03
PublicationDate_xml – month: 11
  year: 2018
  text: 2018-11-03
  day: 03
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Alzheimer's research & therapy
PublicationTitleAbbrev Alz Res Therapy
PublicationTitleAlternate Alzheimers Res Ther
PublicationYear 2018
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References AM Fagan (439_CR4) 2014; 6
W PSJ (439_CR7) 2017; 89
N Mattsson (439_CR14) 2013; 9
J Fortea (439_CR5) 2011; 8
P Steinacker (439_CR17) 2016; 6
G Disanto (439_CR11) 2017; 81
H Zetterberg (439_CR15) 2016; 91
CH Lu (439_CR16) 2015; 84
SM Mills (439_CR3) 2013; 169
N Mattsson (439_CR6) 2017; 74
RJ Bateman (439_CR13) 2012; 367
MC Carrillo (439_CR2) 2013; 9
M Gunnarsson (439_CR18) 2011; 69
R Sala-Llonch (439_CR12) 2015; 36
LH Meeter (439_CR19) 2016; 3
JD Rohrer (439_CR8) 2016; 87
LM Byrne (439_CR10) 2017; 16
RJ Bateman (439_CR1) 2011; 3
JC Rojas (439_CR9) 2016; 3
P Weydt (439_CR20) 2016; 79
References_xml – volume: 9
  start-page: 251
  year: 2013
  ident: 439_CR14
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2013.01.010
– volume: 3
  start-page: 623
  issue: 8
  year: 2016
  ident: 439_CR19
  publication-title: Ann Clin Transl Neurol
  doi: 10.1002/acn3.325
– volume: 8
  start-page: 202
  year: 2011
  ident: 439_CR5
  publication-title: Neurodegener Dis
  doi: 10.1159/000322229
– volume: 74
  start-page: 557
  year: 2017
  ident: 439_CR6
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2016.6117
– volume: 169
  start-page: 737
  year: 2013
  ident: 439_CR3
  publication-title: Rev Neurol (Paris)
  doi: 10.1016/j.neurol.2013.07.017
– volume: 89
  start-page: 2167
  issue: 21
  year: 2017
  ident: 439_CR7
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000004667
– volume: 81
  start-page: 857
  year: 2017
  ident: 439_CR11
  publication-title: Ann Neurol
  doi: 10.1002/ana.24954
– volume: 3
  start-page: 216
  year: 2016
  ident: 439_CR9
  publication-title: Ann Clin Transl Neurol
  doi: 10.1002/acn3.290
– volume: 3
  start-page: 1
  issue: 1
  year: 2011
  ident: 439_CR1
  publication-title: Alzheimers Res Ther
  doi: 10.1186/alzrt59
– volume: 87
  start-page: 1329
  issue: 13
  year: 2016
  ident: 439_CR8
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000003154
– volume: 69
  start-page: 83
  issue: 1
  year: 2011
  ident: 439_CR18
  publication-title: Ann Neurol
  doi: 10.1002/ana.22247
– volume: 36
  start-page: 1261
  year: 2015
  ident: 439_CR12
  publication-title: Neurobiol Aging
  doi: 10.1016/j.neurobiolaging.2014.12.022
– volume: 6
  year: 2016
  ident: 439_CR17
  publication-title: Sci Rep
  doi: 10.1038/srep38737
– volume: 367
  start-page: 795
  issue: 9
  year: 2012
  ident: 439_CR13
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1202753
– volume: 91
  start-page: 1
  issue: 1
  year: 2016
  ident: 439_CR15
  publication-title: Neuron
  doi: 10.1016/j.neuron.2016.06.030
– volume: 79
  start-page: 152
  issue: 1
  year: 2016
  ident: 439_CR20
  publication-title: Ann Neurol
  doi: 10.1002/ana.24552
– volume: 16
  start-page: 601
  year: 2017
  ident: 439_CR10
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(17)30124-2
– volume: 84
  start-page: 2247
  year: 2015
  ident: 439_CR16
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000001642
– volume: 9
  start-page: 123
  year: 2013
  ident: 439_CR2
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2012.12.004
– volume: 6
  start-page: 226ra30
  issue: 226
  year: 2014
  ident: 439_CR4
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3007901
SSID ssj0066284
Score 2.4037368
Snippet Background Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether serum...
Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer's disease (ADAD) are needed. We investigate whether serum neurofilament...
Background Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer's disease (ADAD) are needed. We investigate whether serum...
Background Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether serum...
BackgroundBiomarkers that can track disease onset and progression in autosomal dominant Alzheimer's disease (ADAD) are needed. We investigate whether serum...
Abstract Background Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether...
SourceID doaj
swepub
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 113
SubjectTerms Alzheimer's disease
Amyotrophic lateral sclerosis
association
biomarker
Biomarkers
Biomedical and Life Sciences
Biomedicine
Care and treatment
chain
Cytoplasmic filaments
Dementia
Familial Alzheimer's disease
frontotemporal dementia
Geriatric Psychiatry
Geriatrics/Gerontology
Immunoassay
Light
Multiple sclerosis
Mutation
Neurodegeneration
Neurofilament light
Neurologi
Neurology
Neurosciences
Neurosciences & Neurology
Presenilin 1
Prevention
protein
Quality control
trials
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQiFeggJEQSKCoTpyHc1wQVYUEJyr1ZvmV7Up5VJvNoZy48wv4e_wSZuxsaIpULlzjsZN4xvOwx98Q8spyi8dVPDapE3GWWxsLXbOYmVRry7V2Di8Kf_5SnJxmn87ysyulvjAnLMADh4k7woicK5A9k9ZZaZ1KeFIbAZ645pUzHgmUVWwfTAUdXBSgdaczzEQURwN0wpvIiYjxKmh8ubBCHqz_b5V8xSZdz5ecD02vAYx6o3R8l9yZvEm6Cn9xj9xy3X3yA9b_2FKPVFlvgOMwHm0wCKcNpggN1GBJjga8TIrbsBSMo8MadrQNG4YDVZ0N_a1be1xqZB9tMZVnO9BNR9W464e-hXfbPiTT0FXz7dxtWrf99f3nQKeDnwfk9Pjj1w8n8VRzITZFme5iw-qSW5cJxjNT1sIAL10llOCqAk9QZwkzJatUovPU5EYJAaF5mnCIdQugYfwhOej6zj0m1FZF4jTTjpcWgvBUZblWTuV1abQRnEeE7XkgzQRIjnUxGukDE1HIwDYJbJPINnkZkbdzl4uAxnET8Xtk7EyIQNr-AYiXnMRL_ku8IvICxUKGW6mzOpCrHDfgwPkSEXnjKVAhwOcbNd1rgElAaK0F5eGCEhayWTbvRU9OimSQMLU52DKIlCPycm7Gnpgc17l-9DQIpcZFGZFHQVLnnwYPpQIvEgYvFzK8mJVlS7c59zDjRYqxAIz5bi_tfz7rhkl_HRbE4gXr8ULCo_UoByfBYS4Ze_I_uPOU3E5xUeM2Pz8kB7vt6J6Bk7jTz70--A1VSWf3
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LjtMw0ILlwgWBeAUWMBICCRStEyexc0IFsVohwYmVerPiR7qV2qQ0zWE5cecL-D2-hBnHzZJF6jUeO7bn4ZnxeIaQV5ZbvK7isUmdjLPc2ljqmsXMpFpbrrVz-FD4y9fi7Dz7PM_nweHWhbDKvUz0gtq2Bn3kJ2nCc2BqMBneb77HWDUKb1dDCY2b5FYCmgiWbhDz0eAqCpC94SYzkcVJl3CsTMgSGeOD0Phychb5lP3_C-Z_TqbrUZPj1em1NKP-aDq9S-4EnZLOBiK4R2645j75BVKgX1Ofr7JeAt5hPLpCU5yuMFCoowYLc6xA16TojKVwRDqsZEfXg9uwo1Vjh_7WLXx2akQiXWNAz7ajy4ZW_a7t2jX827ZDSA2drX5cuOXabf_8_N3RcP3zgJyffvr28SwOlRdiU4h0FxtWC25dJhnPjKilAYy6UlaSVyXogzpLmBGsrBKdpyY3lZRgoAOGwOItAIbxh-SoaRv3mFBbFonTTDsuLJjiaZXlunJVXgujjeQ8ImyPA2VCWnKsjrFS3jyRhRrQpgBtCtGmLiPyduyyGXJyHAL-gIgdATGdtv_QbhcqcKdCtw9Mm3GT1pmwroJRaiPB3NO8dCaLyAskCzW8TR2Fgprl6IYDFUxG5I2HQLEA0zdVeN0Am4AJtiaQxxNIYGczbd6TngripFNXxB-Rl2Mz9sQQuca1vYfBhGpciog8Gih1XDToKSXokjC4mNDwZFemLc3ywicbL1K0CGDMd3tqv5rWgU1_PTDE5AeLfqPg06JXnVOgNgvGnhxe7VNyO0V2RTc-PyZHu23vnoESuNPPPaf_Bc5XX9s
  priority: 102
  providerName: ProQuest
Title Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease
URI https://link.springer.com/article/10.1186/s13195-018-0439-y
https://www.ncbi.nlm.nih.gov/pubmed/30390718
https://www.proquest.com/docview/2135467026
https://www.proquest.com/docview/2130055387
https://pubmed.ncbi.nlm.nih.gov/PMC6215337
https://gup.ub.gu.se/publication/273700
https://doaj.org/article/01503a003c2f47dea131fc8086b39ec4
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZoe-GCQLwCZTESAgkU4cRJ7By3q1YVEhVCVNqbFT-yXSmbrTabQzlx5xfw9_glzDjZ0BRUias9dhzPwzNj-zMhry23uF3FQxM7GSaptaHUJQuZibW2XGvn8KLwp7Ps9Dz5OE_nPVg03oW5vn8fyexDE3F8TZBFMsRLnOHVHjlIwe6iMM-y2c7oZhmY2X7T8p_NRsuOR-f_2wZfW4RuHpAcdklvIIr6VejkPrnXu4902vH7Abnj6ofkByh8u6IemrJcAouhP1ph1E0rPBPUUINvcFTgVlLMu1JYDR0-WkdXXYawoUVtu_bWLTwQNfKLrvDszqahy5oW7XbdrFfwbbvuTs_QafXtwi1XbvPr-8-G9js9j8j5yfHX2WnYP7IQmkzE29CwUnDrEsl4YkQpDTDP5bKQvMjB9dNJxIxgeRHpNDapKaSEWDyOOAS3GdAw_pjs1-vaPSXU5lnkNNOOCwtRd1wkqS5ckZbCaCM5Dwjb8UCZHoEcH8KolI9EZKY6tilgm0K2qauAvBuaXHbwG7cRHyFjB0JEzvYFIFCqV0SFGR4YNuMmLhNhXQG9lEZCZKd57kwSkJcoFqq7hjrov5qmmHEDb0sG5K2nQAsAwzdFf5EBJgGxtEaUhyNK0Fwzrt6JnuotR6NgalNYvCA0DsiroRpb4mm42q1bT4PYaVyKgDzpJHX4aXBJcnAboXMxkuHRrIxr6uWFxxXPYnT-oc_3O2n_M6xbJv1NpxCjDyzaSwVFi1Y1ToGHLBh79l_dPid3Y9ReTODzQ7K_3bTuBbh_Wz0he2IuJuTg6Pjs85eJNwMTn0r5DdSeXGg
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtNAcFXSA1wQiFeg0EXiIYGsrr1-rA8VSqFVStsIoVbqbfE-nEZK7BAnQuHEnS_gZ_gYvoQZP1JcpNx6tWfX653Z2XkPIS8MN-iu4o72rHD8wBhHqJQ5THtKGa6UtZgofDII-2f-x_PgfIP8bnJhMKyy4Ykloza5Rhv5jufyAA41qAzvpl8d7BqF3tWmhUZSt1Ywu2WJsTqx48guv4EKV-wefgB8v_S8g_3T932n7jLg6DDy5o5macSN9QXjvo5SoWH1NhaJ4EkMso_yXaYjFieuCjwd6EQIUEZhNaDdhQDDOMx7g2z6aEDpkM29_cGnz81dEIbA_WtfqivCncLl2BuRucLBlFRn2boNy6YB_18N_9yNV-M2V87bK4VOy8vx4A65XUu1tFeR4V2yYbN75CfwocWElhUz0xFQHsxHx2gMoGMMVSqoxtYgY5B2KZqDKVzSFnvp0UlluCxokplqvLHDsj42khGdYEjRrKCjjCaLeV7kE_i2yaugHtobf7-wo4md_fnxq6C1A-o-ObsWrDwgnSzP7CNCTRy6VjFleWT8MPYSP1CJTYI00koLzruENTiQui6Mjv05xrJUkEQoK7RJQJtEtMlll7xZDZlWVUHWAe8hYleAWNC7fJDPhrLmDxINT7BsxrWX-pGxCcySagEKp-Kx1X6XbCNZyCo7dsWWZC9AQyAIgaJLXpcQyJhg-Tqp8ytgE7DEVwtyqwUJDEW3XzekJ2uGVsjL49clz1evcSQG6WU2X5QwWNKNi6hLHlaUuvppkJRikGZh8qhFw61dab_JRhdlufPQQ50E5nzbUPvlstZs-qvqQLQ-MFxMJTwaLmRhJQjuEWOP1__tNrnZPz05lseHg6Mn5JaHRxedCnyLdOazhX0KIulcPavPPSVfrpvV_AU7qaHb
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSIgLAvEKFGokBBIoqhPn4RyXhVV5VRyo1JsVP7JdKZusNptDOXHnF_D3-CXMxEkgBVXiao8dxzMez9jjbwh5ZrjB6yru69AKP4qN8YUqmM90qJThSlmLD4U_HSdHJ9H70_i0z3PaDNHuw5Wke9OAKE3V7nBjCrfERXLYBBxzDLJA-Pi00z-_Sq4hVBfG9M2T-aCKkwSUb3-V-c9mk82ow-z_WzP_sTVdDJsc704v4Ix2e9PiFrnZG5V05qTgNrliqzvkO6iBdk07wMpiBYyH_miJvjgtMVKooRozc5RgbFI8jaWwR1pMZUfX7tywoXllXHtjlx08NXKRrjGiZ9vQVUXzdlc39Rq-bWoXU0Nn5dczu1rb7c9vPxra3__cJSeLt1_mR36fesHXSRrufM2KlBsbCcYjnRZCA0ttJnLB8wwMQhUFTKcsywMVhzrWuRDgoYcBB5c3ARrG75G9qq7sA0JNlgRWMWV5asAXD_MoVrnN4yLVSgvOPcIGHkjd45JjeoxSdv6JSKRjmwS2SWSbPPfIy7HJxoFyXEb8Ghk7EiKedldQb5eyX54Sz31g2IzrsIhSY3PopdAC_D3FM6sjjxygWEj3OHXUCnIW4zkc2GDCIy86CtQLMHyd988bYBIQYWtCuT-hhPWsp9WD6MlenzQSpjaGLQ0cZo88HauxJcbIVbZuOxpEVOMi9ch9J6njT4OhkoExCZ2nExmezMq0plqddWjjSYguAfT5apD238O6ZNKfuwUx-cCy3UgoWraysRLs5pSxh__V7QG5_vnNQn58d_zhEbkR4kLGE36-T_Z229Y-Bvtwp550OuAX91VkMQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+neurofilament+light+levels+correlate+with+severity+measures+and+neurodegeneration+markers+in+autosomal+dominant+Alzheimer%E2%80%99s+disease&rft.jtitle=Alzheimer%27s+research+%26+therapy&rft.au=S%C3%A1nchez-Valle%2C+Raquel&rft.au=Heslegrave%2C+Amanda&rft.au=Foiani%2C+Martha+S.&rft.au=Bosch%2C+Beatriz&rft.date=2018-11-03&rft.issn=1758-9193&rft.eissn=1758-9193&rft.volume=10&rft.issue=1&rft_id=info:doi/10.1186%2Fs13195-018-0439-y&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13195_018_0439_y
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1758-9193&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1758-9193&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1758-9193&client=summon